Dr. Keith Allen MD

Director, Cardiothoracic Vascular Surgery Research, Mid America Heart & Lung Surgeons, PC

GLG News by Dr. Keith Allen MD, Director, Cardiothoracic Vascular Surgery Research

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Drug Eluting Stents:The Next Vioxx

December 14, 2006

Analysis of:Trading restenosis for Thrombosis? New questions about drug-eluding stents. | content.nejm.org

1. DES whether used on or off label will likely require life long anticoagulation with Plavix like drugs.

2. The incidence of late thrombosis is significant when anticoagulation is interrupted for events such as elective surgery.

3. Unlike restenosis following insertion of a bare metal stent which rarely results in death to the patient, late thrombosis following use of a DES results in a 50% mortality.

4. Hints of this problem were present during FDA presentations prior to DES approval which may lead to significant liability as this problem becomes more apparent.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS